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Pharmacogenomics

In vivo characterization of CYP2D6*12,
*29 and *84 using dextromethorphan as a
probe drug: a case report

CYP2D6*84 was first described in a Black South African subject, however, its function
remains unknown. Astrolabe, a probabilistic scoring tool developed in our laboratory
to call genotypes from whole genome sequence, identified CYP2D6*84 in a trio. The
father presented with intermediate metabolism when challenged with the CYP2D6
probe drug dextromethorphan (DM/dextrorphan [DX] = 0.0839). Since his second
allele, CYP2D6*12, is nonfunctional, the observed activity is derived by CYP2D6*84.
This finding suggests that the allele’s hallmark P267H causes decreased activity toward
DM and that this allele should receive a value of 0.5 for Activity Score calculations. The
mother’s DM/DX of 0.0543 was consistent with the decreased activity classification of
CYP2D6*29. The child, a critically ill neonate, was not phenotyped, but predicted to
be a normal metabolizer.
First draft submitted: 8 December 2016; Accepted for publication: 13 January 2017;
Published online: 14 March 2017
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Although CYP2D6 is among the best characterized drug-metabolizing enzymes, there
is no information regarding function for
many of the allelic variants described by
the Human Cytochrome P450 (CYP) Allele
Nomenclature Database [1] . Indeed, of the
109 defined allelic variants, function for
47 variants remains unknown or has only
been investigated in vitro per the recent
update of the Clinical Pharmacogenetics
Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes
and dosing of tricyclic antidepressants [2] .
This information void can be attributed to
a number of factors including the use of deidentified subjects in the detection of novel
variants through sequencing studies making
subjects unavailable for follow-up pheno
typing, and the relative low frequency of
those variants making it difficult to not only
identify individuals carrying the variant of
interest but also to identify subjects with an
informative diplotype. As next-generation
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sequencing (NGS) platforms are increasingly employed for gene analysis in both
the research and clinical settings, the detection of rare variants, including many of the
47 alleles currently classified as unknown
function by CPIC, will become routine.
Thus, the absence of information regarding the activity of these alleles will limit
the translation of patient diplotypes into
predicted phenotypes [2–5] .
The CYP2D6*84 allele was first described
in 2013 by Dodgen et al. in a Black South
African subject by sequence analysis [6] , but
no additional information regarding this
variant has emerged in the literature since
its discovery. We have previously identified
CYP2D6*84 in one subject of a trio (subject
Children’s Mercy Hospital [CMH] 631 [7])
using a bioinformatic tool, Astrolabe (initially named ‘Constellation’ [7,8]) that facilitates CYP2D6 genotype calling from whole
genome sequence data. Astrolabe has now
identified this allele in two additional sub-
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jects of another trio, a father and a critically ill neonate. However, due to the unknown functional status
of CYP2D6*84, we were unable to predict the pheno
type of the individuals carrying this allele with a priori
data.
This case report describes confirmatory Sanger
resequencing of the alleles found in the second trio
including CYP2D6*84. Both parents have genotypes
consisting of known nonfunctional alleles that allowed
us to determine the activity of CYP2D6*84 and confirm activity of CYP2D6*29 in these individuals with
the CYP2D6 probe drug dextromethorphan (DM).
The urinary metabolic ratio of DM over its metabolite dextrorphan (DX) served as a measure of CYP2D6
activity and thereby determines allele function and
phenotype status [9] .
Methods
This study was approved by the Institutional Review
Board of Children’s Mercy Kansas City. Informed
written consent was obtained from the parents of the
trios.
Whole genome sequence was performed as previously described [7,10] . Briefly, a library was constructed
with the TruSeq DNA PCR-Free Library Prep Kit
(Illumina, San Diego, CA, USA) according to the
manufacturer’s protocol and sequenced on an Illumina
HiSeq 2500 instrument using paired end 100-bp reads
to a read depth of at least 30×. Samples were aligned
to the GRCh37.p13 reference genome with bwa-mem
v.0.7.12 and variants called with the Genome Analysis ToolKit v.3.2-2 producing variants relative to the
CYP2D6*2 reference [10] . Subsequently, CYP2D6
diplotypes were called using a version of Astrolabe
that has been improved since it was first published [7] .
Astrolabe is available through the Children’s Mercy
website [11] . Variants across the entire CYP2D6 gene
locus were manually inspected to validate A strolabe
calls.
Allele-specific long-range PCR was performed as
previously described [12] . Specifically, we amplified the
CYP2D6*84 (child), *4, *29 (mother) and *12 (father)
alleles and Sanger-sequenced the resulting XL-PCR
fragments using BigDye Terminator chemistry and a
3730 DNA analyzer (Thermo Fisher Scientific, MA,
USA).
For phenotyping, subjects self-administered 30 mg
of DM (Robitussin® cough syrup, NC, USA) after
voiding their bladder. Urine was collected for 4 h. DM
and DX were measured by NMS Labs (PA, USA). The
urinary metabolic ratio of DM/DX served as a measure of CYP2D6 activity. Classification into poor,
intermediate, normal (formerly known as extensive
[13]) and ultra-rapid metabolizer phenotype groups has
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previously been described. Specifically, intermediate
metabolizers are defined as 0.03 ≤ DM/DX <0.3 [14] .
The following databases were utilized to obtain information regarding allele frequencies: the CMH Variant
Warehouse at the Center for Pediatric Genomic Medicine at Children’s Mercy Kansas City [15] , the SPHINX
database, a resource of the eMERGE Network [16] , the
Exome Aggregation Consortium (ExAC) database [17]
and the NHLBI Exome Sequencing Project Exome
Variant Server (EVS) [18] .
Results & discussion
Allelic variation

Astrolabe called the following genotypes for the trio:
CYP2D6*4xN/*29 (mother), CYP2D6*12/*84 (father)
and *29/*84 (child). Astrolabe calls were confirmed by
Sanger sequencing of allele-specific CYP2D6*4, *12,
*29 and*84 XL-PCR fragments. CYP2D6*4 matched
100% with the *4D sequence we have described previously (case 21, in Gaedigk et al. [19] , data not shown).
In contrast, as summarized in Supplementary Figure 1,
CYP2D6*12, *29 and*84 deviated from the definitions
listed by the P450 nomenclature database.
The CYP2D6*84 allele matched 100% with the
one we identified in our first trio (subject CMH 631
described by Twist et al. [7]), but lacks two SNPs,
one in intron 7 and one in the upstream region compared with the variant described by Dodgen et al. [6]
on which the nomenclature is based for this allele.
Interestingly, the CYP2D6*84 recently described by
Chaudhry et al. [20] , which matches CYP2D6*84var,
was found in a subject recruited from the same geographical region as the individual in which this variant was first discovered [6] . The CYP2D6*12 allele
was first described in 1996 and at that time defined
by variations in exon regions only, in other words, it
is unknown whether there are SNPs in introns and/or
the 3′- and 5′-UTRs. Although these SNPs do not contribute to the function of this particular allele, having precise haplotype definitions facilitates automated
diplotype calling using bioinformatic tools such as
Astrolabe [7] . As shown in Supplementary Figure 1, the
CYP2D6*12 in our trio features the ‘key’ SNP defining
this allele (124G>A, G42R, rs5030862), but also carries three additional exonic SNPs (1716G>A, E155K,
rs28371710; 2575C>A, rs28371718 and 3254T>C,
rs28371726). However, the latter are not novel per se,
as these SNPs are part of the CYP2D6*45 and *46
haplotype definitions. A search of the CMH Variant
Warehouse for the CYP2D6*12 key SNP (rs5030862)
identified a second subject besides the father of the trio
investigated here. Furthermore, this subject also has
the three additional SNPs (1716G>A, 2575C>A and
3254T>C) suggesting that this CYP2D6*12 allele is
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Table 1. Allele frequencies of rs148382141, the key SNP defining CYP2D6*84.
Database

Subjects (n)

MAF (%) all
subjects

MAF (%) African
ancestry

MAF (%)
European
ancestry

CMH variant warehouse

3432

0.044

NA

NA

SPHINX database

9015

0.00555

0.0072

0

ExAC

21,521

0.02567

0.2759

0

EVS

6478

0.01003

0.2964

0

SPHINX data as per update of July 2015; CMH variant warehouse and ExAC accessed 22 November 2016. The CYP2D6*84-defining SNP
rs148769737 (Chr22:42524219 T/A) was not observed in the ExAC database among south or east Asians subjects but was discovered in
Latino and Europeans (non-Finnish) subjects at frequencies of 0.0000978 and 0.00003349, respectively.
CMH: Children’s Mercy Hospital; EVS: Exome variant server; ExAC: Exome Aggregation Consortium; MAF: Minor allele frequency; NA: Not
available.

identical to the subvariant we have Sanger-sequenced
for this study. Considering the presence of these additional SNPs of which one is nonsynonymous, the
CYP2D6*12 identified in this study in two subjects is
more accurately described as a subvariant.
CYP2D6*29 is another allele for which the
nomenclature database only lists variations in exons.
The mother’s CYP2D6*29 allele carried all exonic
SNPs listed by the database, but also had numerous SNPs across introns and untranslated regions
(Supplementary Figure 1) . This CYP2D6*29 sequence
matched those obtained from two Coriell samples,
NA17131 and NA19109. However, this variant differed from a CYP2D6*29 sequence we obtained from
a subject who participated in a previous study, but was
not published in that report [21] .
The P450 Nomenclature database does not assign
star (*) allele designations for subvariants. Because
there is currently no system in place that designates
suballelic variants, the novel CYP2D6*12, *29 and *84
variants identified in this study are labeled with ‘var’.
Allele frequencies

CYP2D6*84 is a rare variant that appears to be present
predominantly in subjects with Black African ancestry (Table 1) . The frequency of the key SNP identify-

ing CYP2D6*84 (2574C>A, P267H, rs148769737)
was 0.044% in the CMH Variant Warehouse (three
heterozygous subjects among 3432). One of those subjects (CMH 631 described previously [7]) was genotyped as CYP2D6*17/*84. Although the ethnicity of
this subject is unknown, we speculate that this person is of African ancestry because of the presence of
CYP2D6*17, which is almost exclusively found in African populations or populations with African admixture (see CYP2D6 allele frequency table available at
the PharmGBK website [22,23]). The other two subjects
are the father and child described in this report. Our
Variant Warehouse frequency, albeit not derived from
unrelated subjects only, is in line with those reported
by the SPHINX and ExAC databases (Table 1) . Taken
together, these data suggest that CYP2D6*84 is predominantly present in African populations and subjects with African ancestry. The CYP2D6*12 allele
also appears to be rare and, as shown in Table 2, has
been found predominantly in subjects with African
ancestry. However, two subjects with CYP2D6*84
were found in two studies conducted in South African
subjects (n = 100 [6] and n = 31 [20] , respectively), which
suggest an allele frequency of 0.76%, which is considerably higher compared with the frequencies reported
by a number of databases (Table 1) . Whether this allele

Table 2. Allele frequencies of rs5030862, the key SNP defining CYP2D6*12.
Database

Subjects (n)

MAF (%) all
subjects

MAF (%) African
ancestry

MAF (%)
European
ancestry

CMH variant warehouse

3432

0.029

NA

NA

SPHINX database

9015

0.0222074

0.148258

0

ExAC

51,296

0.003899

0.03575

0.001748

EVS

6491

0.0231

0.0455

0.0116

SPHINX data as per update of July 2015; CMH variant warehouse and ExAC accessed 22 November 2016. The CYP2D6*12 defining SNP
rs5030862 (Chr22: 42526670) was not observed in the ExAC database among south Asian, east Asians or Latino subjects, but was
discovered in Europeans (non-Finnish) at a frequency of 0.00001748.
CMH: Children’s Mercy Hospital; EVS: Exome variant server; ExAC: Exome Aggregation Consortium; MAF: Minor allele frequency; NA: Not
available.
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is indeed more common in this particular population
warrants further investigation.
Phenotype prediction from genotype data
& in vivo phenotyping using DM

Because of the ‘unknown’ function status of CYP2D6*84,
the father’s phenotype was predicted to be either a poor
metabolizer (activity score = 0), intermediate metabolizer (activity score = 0.5) or normal metabolizer (activity score = 1) depending on whether CYP2D6*84 is a
no, decreased or normal function allele. The mother’s
genotype received an activity score of 0.5 predicting an
intermediate metabolizer phenotype status based on the
decreased function categorization of CYP2D6*29. The
prediction was intermediate or normal metabolizer for
the child (translation into phenotype according to the
updated CPIC translation table [22]).
The father uniquely presented us with a rare opportunity to measure CYP2D6 activity in vivo that is solely
derived from CYP2D6*84. Only about 1 in 10,000
individuals carries a genotype consisting of a non
functional allele that is paired with CYP2D6*84 such
as the father’s, in other words, CYP2D6*12/*84. In vivo
phenotyping determined a urinary metabolic ratio of
DM/DX of 0.0839 categorizing the father as inter
mediate metabolizer. The allele-defining SNP in exon 5
(2574C>A) causes an amino acid change (P267H) that
is predicted by SIFT to be damaging (score of 0.03) [24]
and by PolyPhen to be probably damaging (score of
0.977) [25] . Decreased activity, as indicated by a urinary
metabolic ratio of DM/DX of 0.0839 is consistent with
the in silico predictions and might be explained by a difference in the charge caused by the proline to histidine
change. Based on these findings, CYP2D6*84 should
be classified as ‘decreased’ and receive a value of 0.5 for
Activity Score calculations.
The mother’s DM/DX ratio was 0.0543 classifying
her as an intermediate metabolizer that was expected
given her genotype (CYP2D6*4×2/*29). Decreased
activity is consistent with published data describing CYP2D6*29 as a variant encoding protein with
compromised function [21,26] .

The child, a critically ill neonate was not subjected
to phenotyping. Based on the parent’s phenotype information, the child’s diplotype (CYP2D6*29/*84) was
calculated to have an Activity Score of 1 predicting
normal metabolism, which provided valuable information to parents and providers caring for this complex
patient.
Conclusion
In vivo phenotyping of an individual with an informative CYP2D6 diplotype allowed us to determine
CYP2D6*84 activity for the first time. This information is invaluable to predict CYP2D6 activity in
patients carrying this allelic variant.
Future perspective
As genotype testing is increasingly performed using
NGS platforms, rare alleles will reveal themselves, but
will elude interpretation due to the lack of data. The
development of protocols allowing follow-up phenotype studies are warranted to functionally characterize
the increasing number of allelic variants and diplotype
combinations discovered by NGS to accurately predict
phenotype and aid thereby move individualized drug
therapy forward.
Supplementary data
To view the supplementary data that accompany this paper,
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Executive summary
• CYP2D6*84 is a rare variant predominantly observed in Africans and subjects with African ancestry. It was first
discovered in a South African individual in 2013.
• Because CYP2D6*84 function remained unknown, phenotype could not be predicted, or only approximated,
from diplotypes containing this allele.
• Astrolabe, a tool to call genotypes from next-generation sequencing data, correctly identified the CYP2D6*84
allele in three individuals of two trios (one trio described in this report).
• Allele calls were verified by Sanger sequencing and an individual with a CYP2D6*12/*84 genotype subjected
to in vivo phenotyping using the CYP2D6 probe drug dextromethorphan.
• The urinary metabolic ratio of dextromethorphan to its metabolite dextrorphan (DM/DX) indicated that
CYP2D6*84 encodes decreased function. This finding is consistent with in silico predictions.
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